Medical Aesthetics Market Growth Continues to Shine in Healthcare Industry

PALM BEACH, Florida, November 20, 2017 /PRNewswire/ --

Medical aesthetics is a fusion of healthcare and beauty services to provide high-technology skin care that involves significant cosmetic change or enhancement. The treatments employed include injections of Botox and dermal facial fillers, body contouring, laser hair removal, chemical peels, many others. The global medical aesthetics market is estimated to grow at a CAGR of 10.8% from 2016 to 2021, projected to reach USD 13.29 billion. The adoption of aesthetic procedures is rising across the globe due to the growing aging population, increasing awareness about cosmetic procedures, growing safety and efficacy of aesthetic procedures owing to technological advancements, and rising middle class population. A steady inclination towards minimally invasive and non-invasive aesthetic procedures, rising demand for aesthetic treatments among the male population, and rapid growth in number of cosmetic procedures are driving the growth for the industry. Active in the markets today include: Milestone Scientific Inc. (NYSE: MLSS), Allergen plc (NYSE: AGN), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Merck & Co. Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE),

Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that deliver painless and precise injections, today announced plans for the commercial launch of its novel and proprietary cosmetic injection instrument for delivery of botulinum toxin (such as Botox® and Dysport®).

Key highlights of the new cosmetic instrument include:

•    Improved needle placement with a comfortable stylus grip

•    Precise dosing driven by an electronic motor

•    Uses the same comfort speed technology that has made dental injections painless

•    Efficient operation with an intuitive touch-screen interface

•    Simple integrated electronic record-keeping capability without a costly electronic medical records system

•    Operates wirelessly with high-capacity battery

Leslie Bernhard, Chairman and Interim CEO of Milestone Scientific, commented, "There is a large and growing market for botulinum toxin (such as Botox® and Dysport®) injections globally, with over 8.4 million botulinum toxin injections annually in the U.S. alone. Recognizing this opportunity, we set out to develop a product concept and conducted a cosmetic injection instrument feasibility study to determine professional interest in a new cosmetic injection system. Read this and more news for Milestone Scientific covered by SmallCapStocks.com at:  https://www.smallcapstocks.com/mlss/